<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138969</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS98-CT6-12</org_study_id>
    <nct_id>NCT01138969</nct_id>
  </id_info>
  <brief_title>Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer</brief_title>
  <official_title>Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the prospective, randomized study is to investigate the efficacy of PPI in
      prevention of ulcer recurrence for clopidogrel users. We plan to enroll 300 clopidogrel users
      without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly
      assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel
      treatment alone for 6 months. The ulcer recurrence rate between the treatment groups will be
      compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Peptic Ulcer</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with recurrent peptic ulcer within 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peptic Ulcer Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>participants with peptic ulcer bleeding within 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Esomeprazole plus clopidogrel group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>clopidogrel 75 mg qd for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>esomeprazole 20 mg qd for 6 months</description>
    <arm_group_label>Esomeprazole plus clopidogrel group</arm_group_label>
    <other_name>plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at
             initial endoscopy. The patients will be randomly assigned to receive either (1)
             esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6
             months.

        Exclusion Criteria:

          -  1.serious disease 2.refuse informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwok-Hung Lai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <results_first_submitted>December 31, 2012</results_first_submitted>
  <results_first_submitted_qc>December 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2013</results_first_posted>
  <last_update_submitted>September 6, 2015</last_update_submitted>
  <last_update_submitted_qc>September 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Ping-I (William) Hsu, M.D.</investigator_full_name>
    <investigator_title>Chief, Gastroenterology Division</investigator_title>
  </responsible_party>
  <keyword>proton pump inhibitor</keyword>
  <keyword>peptic ulcer</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of the recruitment period: From August 2008 to August 2012
Type of location: Kaohsiung Veterans General Hospital</recruitment_details>
      <pre_assignment_details>None were excluded following participant enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Esomeprazole Plus Clopidogrel Group</title>
          <description>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel Group</title>
          <description>clopidogrel 75 mg qd for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esomeprazole Plus Clopidogrel Group</title>
          <description>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel Group</title>
          <description>clopidogrel 75 mg qd for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="11.5"/>
                    <measurement group_id="B2" value="73.3" spread="10.7"/>
                    <measurement group_id="B3" value="72.0" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrent Peptic Ulcer</title>
        <description>Number of participants with recurrent peptic ulcer within 6 months</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole Plus Clopidogrel Group</title>
            <description>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Group</title>
            <description>clopidogrel 75 mg qd for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Peptic Ulcer</title>
          <description>Number of participants with recurrent peptic ulcer within 6 months</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peptic Ulcer Bleeding</title>
        <description>participants with peptic ulcer bleeding within 6 months</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole Plus Clopidogrel Group</title>
            <description>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Group</title>
            <description>clopidogrel 75 mg qd for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Peptic Ulcer Bleeding</title>
          <description>participants with peptic ulcer bleeding within 6 months</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Esomeprazole Plus Clopidogrel Group</title>
          <description>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel Group</title>
          <description>clopidogrel 75 mg qd for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>thrombotic events</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarct</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>thrombotic events</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>unstable angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The patients without symptoms who refused follow-up endoscopy were regarded as having no recurrent ulcers. Because peptic ulcer may be asymptomatic, the cumulative number of recurrent peptic ulcer might be underestimated in both groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ping-I Hsu</name_or_title>
      <organization>KaohsiungVGH</organization>
      <phone>886-7-3462121 ext 8233</phone>
      <email>pihsu@isca.vghks.gov.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

